ZLAB Zai Lab Ltd

Price (delayed)

$112.45

Market cap

$10.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.09

Enterprise value

$8.98B

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
ZLAB's gross profit has surged by 171% year-on-year
The equity has soared by 66% from the previous quarter
The quick ratio is down by 17% since the previous quarter but it is up by 11% year-on-year
The debt has contracted by 2.8% YoY but it has grown by 2.4% from the previous quarter
The company's net income has shrunk by 123% YoY
The EPS has plunged by 79% YoY

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
95.41M
Market cap
$10.73B
Enterprise value
$8.98B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.38
Price to sales (P/S)
117.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.48
Earnings
Revenue
$86.78M
EBIT
-$536.46M
EBITDA
-$525.96M
Free cash flow
-$373.56M
Per share
EPS
-$6.09
Free cash flow per share
-$4.12
Book value per share
$17.61
Revenue per share
$0.96
TBVPS
$20.78
Balance sheet
Total assets
$1.9B
Total liabilities
$223.52M
Debt
$18.34M
Equity
$1.67B
Working capital
$1.61B
Liquidity
Debt to equity
0.01
Current ratio
9.33
Quick ratio
9.2
Net debt/EBITDA
3.32
Margins
EBITDA margin
-606.1%
Gross margin
65.3%
Net margin
-618.2%
Operating margin
-620.2%
Efficiency
Return on assets
-43.9%
Return on equity
-50.2%
Return on invested capital
-574.4%
Return on capital employed
-31.5%
Return on sales
-618.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
-6.18%
1 week
-9.35%
1 month
-18.08%
1 year
41.75%
YTD
-16.91%
QTD
-36.47%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$86.78M
Gross profit
$56.65M
Operating income
-$538.23M
Net income
-$536.52M
Gross margin
65.3%
Net margin
-618.2%
ZLAB's gross profit has surged by 171% year-on-year
The company's net income has shrunk by 123% YoY
Zai Lab's operating income has shrunk by 118% YoY
The company's operating margin rose by 28% YoY

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
6.38
P/S
117.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.48
The EPS has plunged by 79% YoY
The equity has soared by 66% from the previous quarter
The stock's P/B is 36% below its last 4 quarters average of 10.6

Efficiency

How efficient is Zai Lab business performance
The ROS has grown by 26% YoY
ZLAB's ROE is up by 10% YoY
The ROA has grown by 9% YoY

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The company's total liabilities has surged by 170% YoY and by 84% QoQ
The total assets has soared by 68% from the previous quarter
The debt is 99% less than the equity
Zai Lab's debt to equity has plunged by 75% YoY and by 50% from the previous quarter
The equity has soared by 66% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.